Abbott Laboratories

• Stryker faced downward pressure and volatility amid pre earnings caution and sector rebalancing. • The company invested four hundred million dollars in CMR Surgical for robotics expansion. • Stryker reported annual revenue of $25.12B and net profit of $3.25B.

• Abbott lowered its full-year comparable sales growth forecast to approximately 6 percent. • The company announced plans to spin off its nutrition segment by late 2027. • Third-quarter revenue and adjusted earnings per share met general market consensus expectations.

• Danaher reported strong third-quarter earnings and upgraded its full-year guidance. • Core revenue growth accelerated alongside notable operating margin expansion and cash flow. • The stock exhibits a MACD buy signal and neutral RSI conditions.

Abbott plans to separate its global Nutrition business, which has approximately $8.5 billion in annual sales, into an independent public company by the end of 2027, subject to customary conditions.

• UnitedHealth exceeded Wall Street expectations with strong third-quarter revenue and earnings. • The medical care ratio improved due to effective cost control and pricing discipline. • Management raised full-year adjusted earnings guidance following robust segment-level momentum.

• Abbott secured FDA approval for its CardioMEMS heart failure system features. • The company reported annual revenue of $44.33B with net profit of $6.52B. • Analysts issued Buy ratings with an average price target of $121.29.